Exciting drug development news for Myelofibrosis patients, aimed at people whose disease had progressed or did not see an adequate response while on Ruxolitinib. A researcher at Mt. Sinai in this video discusses observations from their clinical trial with the drug CPI-0610. Investigators saw improvement in anemia as well as improvement in bone marrow in some patients followed under this clinical trial. As these disorders are related to the bone marrow, this is an exciting development. We will share more news as it becomes available. You can find clinical trials for Polycythemia Vera, Essential Thrombocythemia and Myelofibrosis on our website www.mpnrf.org/Clinical-Trials.
CPI-0610 DEMONSTRATES ACTIVITY IN MF PATIENTS AFTER RUXOLITINIB FAILURE
admin | April 6, 2021